This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chu, Q. S.C. Articles by Rowinsky, E. K. Search for Related Content PubMed PubMed Citation Articles by Chu, Q. S.C. Articles by Rowinsky, E. K.

Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies

Quincy S.C. Chu, Garry Schwartz, Johann de Bono, Deborah A. Smith, Kevin M. Koch, Melissa J. Versola, Lini Pandite, Nikita Arya, Jan Curtright, Ronald A. Fleming, Peter T.C. Ho, Eric K. Rowinsky

From the Institute for Drug Development, Cancer Therapy and Research Center; Brooke Army Medical Center, Fort Sam Houston, San Antonio, TX; and GlaxoSmithKline, Research Triangle Park, NC

Address reprint requests to Quincy S.C. Chu, MD, 11560 University Ave, Edmonton, Alberta T6G 1Z2, Canada; e-mail: quincchu{at}cancerboard.ab.ca

Purpose: This phase I trial (EGF10005) assessed the safety, optimally tolerated regimen (OTR), and pharmacokinetics of lapatinib and capecitabine in combination in patients with advanced solid malignancies.

Patients and Methods: Patients with previously treated, advanced solid malignancies were eligible. Cohorts of at least three patients each received once-daily oral lapatinib (continuous) and capecitabine (twice daily for 14 days every 21 days). Doses of lapatinib and capecitabine were escalated based on dose-limiting toxicities in the first treatment cycle until the OTR was reached. Additional patients were treated at the OTR dose level to further evaluate safety and for pharmacokinetic analyses.

Results: Forty-five patients were treated in the study. The OTR was determined to be lapatinib 1,250 mg/d plus capecitabine 2,000 mg/m²/d. The majority of drug-related adverse events were grade 1 to grade 2 in severity, with few grade 3 and no grade 4 toxicities. The most common drug-related toxicities (> 15% of patients) were diarrhea, nausea, rash, palmar-plantar erythrodysesthesia, mucositis, vomiting, and stomatitis. There were four confirmed responses (one complete response and three partial responses). The pharmacokinetics (area under the curve and maximum concentration) of lapatinib, capecitabine and its metabolites, fluorouracil, and -fluoro-ß-alanine, were not meaningfully altered by coadministration.

Conclusion: Lapatinib and capecitabine administered on a 3-week schedule were well tolerated, and no pharmacokinetic interaction was observed. Clinical activity was observed in patients with previously treated, advanced solid malignancies.

Supported by a grant from GlaxoSmithKline.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2004, New Orleans, LA.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

This article has been cited by other articles:

				B. Paul, J. A. Trovato, and J. Thompson Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1703 - 1710. [Abstract] [Full Text] [PDF]

				P. Paoletti Drug Development in the Targeted Therapy Era J. Clin. Oncol., August 1, 2008; 26(22): 3815 - 3816. [Full Text] [PDF]

				B. Seruga and I. F. Tannock Mathematics in the Realm of Lapatinib: 500 + 500 = 1,500? J. Clin. Oncol., June 20, 2008; 26(18): 2940 - 2942. [Full Text] [PDF]